Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H5GS | ISIN: SE0010323311 | Ticker-Symbol: B9A
Tradegate
05.06.25 | 20:39
18,420 Euro
+0,60 % +0,110
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOARCTIC AB Chart 1 Jahr
5-Tage-Chart
BIOARCTIC AB 5-Tage-Chart
RealtimeGeldBriefZeit
18,33018,49018:20
18,33018,49018:20

Aktuelle News zur BIOARCTIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoBioArctic's Capital Markets Day 2025 - entering a new era of growth187STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event...
► Artikel lesen
22.05.BioArctic AB: Bulletin from the Annual General Meeting in BioArctic AB (publ)106Stockholm, 22 May 2025. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, whereby the following resolutions were made. Adoption of the income...
► Artikel lesen
BIOARCTIC Aktie jetzt für 0€ handeln
22.05.BioArctic AB: BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy143Stockholm, May 22, 2025 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) recommends granting orphan...
► Artikel lesen
21.05.BioArctic AB: Interim Report for the period January - March 2025155Leqembi approved in the EU and billion-dollar license agreement with Bristol Myers Squibb came into effect Events during the first quarter 2025 FDA approved less frequent IV maintenance dosing...
► Artikel lesen
15.05.BioArctic: Eisai projects Leqembi revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)398STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately...
► Artikel lesen
13.05.Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET234STOCKHOLM, May 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January - March 2025 on Wednesday, May 21, 2025...
► Artikel lesen
08.05.BioArctic: Exidavnemab phase 2a study expanded to include MSA patients640STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple...
► Artikel lesen
01.05.BioArctic AB: Sales of Leqembi totaled 14.7 billion yen in the first quarter 202595Stockholm, Sweden, May 1, 2025 - BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2025, in conjunction...
► Artikel lesen
30.04.BIOARCTIC AB: MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer's disease in the UK1
23.04.BioArctic receives European substance patent for exidavnemab2
22.04.BioArctic publishes the Annual Report and Sustainability Report for 20242
22.04.Notice of Annual General Meeting 2025 in BioArctic AB (publ)1
15.04.BioArctic AB: EU approves Leqembi (lecanemab) for treatment of early Alzheimer's disease277Stockholm, April 15, 2025 - The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization...
► Artikel lesen
14.04.BIOARCTIC AB: The European Commission to make final decision on EU Marketing Authorisation for lecanemab8
07.04.BIOARCTIC AB: Exidavnemab and lecanemab data presented at the 2025 AD/PD congress1
01.04.BioArctic: The European Commission refers lecanemab decision to Appeal Committee326STOCKHOLM, April 1, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing...
► Artikel lesen
27.03.Invitation to BioArctic's Capital Markets Day 2025 in Stockholm3
27.03.BIOARCTIC AB: Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD congress1
25.03.BioArctic's partner Eisai presents sales simulation for Leqembi at its annual press conference416STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales...
► Artikel lesen
17.03.BioArctic receives Orphan Drug Designation for exidavnemab the US376STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug...
► Artikel lesen
Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1